VIDEO: FRONTIER-2 study results show IL-23 inhibitor promising in psoriasis

In this Healio exclusive video, Steven R. Feldman, MD, PhD, discussed psoriasis findings from the FRONTIER-2 study presented at the American Academy of Dermatology Annual Meeting.

Feldman, professor of dermatology, pathology and social sciences and health policy at Wake Forest University School of Medicine, discussed the study, which looked into the efficacy and safety of the oral interleukin-23 inhibitor JNJ-2113 (Johnson & Johnson, Protagonist Therapeutics) in the treatment of psoriasis, which showed promising results.

“So far it seems to have the safety profile of an IL-23 inhibitor. So, if we were to get an oral IL-23 inhibitor as safe and effective as the ones we already have, man, I think my patients would be really interested in that,” Feldman said.